Further validation of parkin’s multiple effects that contribute to cellular redox homeostasis could create new opportunities in developing urgently needed therapies for patients with young-onset parkinsonism, and possibly, for those with late-onset PD. This evidence concerns the gene PRKN and Parkinson disease.